L Rami1, J L Molinuevo, R Sanchez-Valle, B Bosch, A Villar. 1. Memory-Alzheimer Unit, Department of Neurology, Institute of Neurosciences, Hospital Clinic i Universitari de Barcelona, Institut d'Investigaciò Biomédica August Pi I Sunyer, Spain. jlmoli@clinic.ub.es
Abstract
OBJECTIVES: To design and validate a new screening test for amnestic Mild Cognitive Impairment (A-MCI) and early stage Alzheimer's disease (AD). METHODS: We develop a verbal episodic and semantic memory test: the Memory Alteration Test (M@T). Discriminative validity was assessed in a population sample of 400 aged individuals from primary care population centres in Barcelona, Spain, 50 patients with A-MCI according to Petersen et al. criteria, and 66 with early AD (Global Deterioration Scale-4 stage) according to the NINCDS-ADRDA criteria. RESULTS: The M@T is quick, 5-min, and easy to administer and to score. M@T mean scores were significantly different between all groups: 41.4 (SD = 4.9) in the primary care population, 31.5 (SD = 3.9) in the A-MCI group and 21.8 (SD = 4.9) in early AD. A cut-off score of 37 points had a sensitivity of 96% and a specificity of 79% for A-MCI diagnosis (AUC = 0.932). A cut-off score of 28 points had a sensitivity of 92% and a specificity of 98% for early AD diagnosis (AUC = 0.99) and a sensitivity of 87 % and specificity of 82% to differentiate between A-MCI and AD patients. CONCLUSION: The M@T provides efficient and valid screening for A-MCI and early stage AD, and discriminates between A-MCI and early AD patients.
OBJECTIVES: To design and validate a new screening test for amnestic Mild Cognitive Impairment (A-MCI) and early stage Alzheimer's disease (AD). METHODS: We develop a verbal episodic and semantic memory test: the Memory Alteration Test (M@T). Discriminative validity was assessed in a population sample of 400 aged individuals from primary care population centres in Barcelona, Spain, 50 patients with A-MCI according to Petersen et al. criteria, and 66 with early AD (Global Deterioration Scale-4 stage) according to the NINCDS-ADRDA criteria. RESULTS: The M@T is quick, 5-min, and easy to administer and to score. M@T mean scores were significantly different between all groups: 41.4 (SD = 4.9) in the primary care population, 31.5 (SD = 3.9) in the A-MCI group and 21.8 (SD = 4.9) in early AD. A cut-off score of 37 points had a sensitivity of 96% and a specificity of 79% for A-MCI diagnosis (AUC = 0.932). A cut-off score of 28 points had a sensitivity of 92% and a specificity of 98% for early AD diagnosis (AUC = 0.99) and a sensitivity of 87 % and specificity of 82% to differentiate between A-MCI and ADpatients. CONCLUSION: The M@T provides efficient and valid screening for A-MCI and early stage AD, and discriminates between A-MCI and early ADpatients.
Authors: Kristen L Sager; Joanne Wuu; Susan E Leurgans; Howard D Rees; Marla Gearing; Elliott J Mufson; Allan I Levey; James J Lah Journal: Ann Neurol Date: 2007-12 Impact factor: 10.422
Authors: Cristóbal Carnero-Pardo; Beatriz Espejo-Martínez; Samuel López-Alcalde; María Espinosa-García; Carmen Sáez-Zea; Elisa Hernández-Torres; José Luis Navarro-Espigares; Rosa Vílchez-Carrillo Journal: PLoS One Date: 2011-11-02 Impact factor: 3.240
Authors: Nilton Custodio; David Lira; Eder Herrera-Perez; Liza Nuñez Del Prado; José Parodi; Erik Guevara-Silva; Sheila Castro-Suarez; Rosa Montesinos; Patricia Cortijo Journal: Dement Geriatr Cogn Dis Extra Date: 2014-08-27
Authors: Nilton Custodio; David Lira; Eder Herrera-Perez; Rosa Montesinos; Sheila Castro-Suarez; José Cuenca-Alfaro; Lucía Valeriano-Lorenzo Journal: Front Aging Neurosci Date: 2017-08-22 Impact factor: 5.750
Authors: Seline Ozer; Krist Noonan; Melanie Burke; John Young; Sally Barber; Anne Forster; Roy Jones Journal: Alzheimers Dement Date: 2016-05-02 Impact factor: 21.566